Fig 1: SOX11 expression in hematological malignancies. (a) Expression boxplots of SOX11 in healthy cells, leukemias, and mantle cell lymphoma. Data sources: Hemap microarray dataset34, GSE4705135, and the PanALL study36. See Supplementary Information for more details. (b) SOX11 expression in ALL cell lines and healthy B- and T-cells, as measured by RT-qPCR (N = 2, black lines indicate the median). ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCL2/MYC, BCL2/MYC rearranged; BCP-ALL, B-cell precursor ALL; CRLF2, CRLF2 (non-Ph-like); DUX4, DUX4 rearranged; E/R, ETV6-RUNX1; HeH, high hyperdiploid; HLF, TCF3/TCF4-HLF; HSC, hematopoietic stem cell; iAMP21, intrachromosomal amplification of chromosome 21; IKZF1 N159Y, IKZF1 missense alteration encoding p.Asn159Tyr; KMT2A, KMT2A rearranged; MCL, mantle cell lymphoma; MEF2D, MEF2D rearranged; NUTM1, NUTM1 rearranged; PAX5alt, PAX5 alterations; PAX5 P80R, PAX5 p.Pro80Arg (P80R) alteration; Ph, Philadelphia chromosome; T/P, TCF3-PBX1; ZNF384, ZNF384 rearranged. Reproduced with permission66.
Fig 2: SOX11 protein expression and impact on the outcome in BCP-ALL. (a) Expression of SOX11 protein by immunohistochemistry. Mantle cell lymphoma (MCL), a strongly positive case for SOX11 (400×); ALL1, a negative B-ALL case (400×); ALL2, a positive B-ALL case (400×); ALL3, a strongly positive B-ALL case (400×). (b) Kaplan–Meier survival curves and Log-rank p-values for OS, EFS, and RFS in the SOX11-positive (high) and -negative (low) groups. Reproduced with permission66.
Fig 3: Detection of SOX11-positive cells by flow cytometry in BCP-ALL. (a) Correlation of CD5 expression with SOX11 mRNA expression in the E/R and T/P subtypes of B-ALL and MCL34. SOX11 expression was categorized into three groups, not detected (ND), low and not detected (ND). (b) Flow cytometry analysis of nuclear SOX11 expression in cell lines with either a low (NALM-6, KOPN-8) or high (REH, RCH-ACV) expression of SOX11. ND, not detected, MCL, mantle cell lymphoma. Reproduced with permission66.
Fig 4: Survival analysis and methylation status of cases with either a high or low SOX11 mRNA expression. (a) Kaplan–Meier survival curves and p-values of Log-rank test for EFS in patients with a low or high expression of SOX11 and in patients with a low or high methylation of the SOX11 gene locus. (b) CpG sites at the SOX11 locus in chromosome 235. (c) DNA methylation at the SOX11 gene locus among patients with either a low or high expression of SOX11. (d) Effect of decitabine treatment on SOX11 mRNA expression in the KOPN-8 cell line. Reproduced with permission66.
Fig 5: Cell viability and transcriptomic changes after knockdown of SOX11. (a) Expression level of SOX11 after knockdown, as analyzed by RT-qPCR (N = 3, black lines indicate the median). (b) Knockdown of SOX11 caused no evident changes in cell viability. Curves are drawn from the biological replicates using the median value at given time points. 697 and RCH-ACV cells represent the T/P subtype, and REH cells represent the E/R subtype. SOX11 knockdown was confirmed by Western blotting, and cell viability assessments were conducted with the AlamarBlue assay. Measured absorbance intensities are reported as x103 (697 N = 6; RCH-ACV and REH N = 4). Western blot gel figures are cropped per cell line from the original blot figures shown in Fig. S3. (c) SOX11 knockdown in 697 cells caused downregulation of genes that are known to be altered after MYC upregulation. (d) Venn diagram of differentially expressed genes in the REH, 697, and RCH-ACV cell lines after knockdown of SOX11 (adjusted p-value < 0.05). (e) Heatmap of 15 concordantly differentially expressed genes in all three cell lines after knockdown of SOX11. Reproduced with permission66.
Supplier Page from Abcam for Anti-SOX11 antibody [EPR8191(2)] (Alexa Fluor® 647)